Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other

Abbott Sues Dexcom Over Breached Settlement Agreement; Bigfoot Clinical Hub Improvements; Hygieia Raises $17M in Series B; ViaCyte’s Ph1/2 VC-02 Preliminary Results Published; Dario Announces New Employer and Provider Contracts

Here is a brief preview of this blast: A series of cardiometabolic-related news items have been observed: Abbott recently filed a lawsuit stating Dexcom allegedly violated a 2014 settlement agreement and asked the court to declare that Abbott doesn't infringe its patents (view article); Bigfoot Biomedical issued a press release highlighting the success of its Bigfoot Unity Diabetes Management Program and Clinic Hub; Hygieia announced it has raised $17M in Series B financing for its AI-driven d-Nav insulin dose automation technology; ViaCyte announced preliminary results of its ongoing, first-in-human Ph1/2 VC-02 trial were published in Cell Stem Cell and Cell Reports Medicine; and Dario announced new employer and provider contracts. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.